"President Trump said the administration has reached agreements with nine more drugmakers to bring their U.S. drug prices more in line with what other wealthy countries pay. Fourteen companies in total have now reached what the administration calls most-favored-nation pricing deals. The companies that took part in Friday's announcement were: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi. They agreed to charge the U.S. government no more for new drugs than the prices paid by other well-off countries."
"In addition, the companies agreed to make some of their most popular drugs available at lower prices to consumers who pay out of pocket through a government website called TrumpRx.com. The TrumpRx website is expected to launch in early 2026, and would take consumers to pharmaceutical companies' direct-to-consumer websites to fulfill orders. For example, Merck will reduce the price of Januvia, a medication for Type 2 diabetes, from $330 to $100 for patients purchasing directly through TrumpRx, the White House said. Amgen will reduce the price of Repatha, a cholesterol-lowering drug, from $573 to $239 when purchased through TrumpRx."
Agreements with nine additional drugmakers bring the total to fourteen companies under most-favored-nation pricing, capping U.S. government payments for new drugs at prices paid by other wealthy countries. State Medicaid programs gain access to lower prices and the companies committed at least $150 billion to U.S. manufacturing. Participating firms will offer some popular medicines at reduced out-of-pocket prices through a planned government portal, TrumpRx.com, launching early 2026, directing buyers to company websites. Examples include Merck's Januvia cut from $330 to $100 and Amgen's Repatha from $573 to $239 via TrumpRx. Companies receive three-year tariff exemptions. Consumer savings remain uncertain given existing low Medicaid prices and insurance copay differences.
Read at www.npr.org
Unable to calculate read time
Collection
[
|
...
]